North America Lymphedema Treatment Market Trends and Analysis by 2028

The lymphedema treatment market in North America is expected to grow from US$ 3,880.04 million in 2021 to US$ 5,419.77 million by 2028; it is estimated to grow at a CAGR of 4.9% from 2021 to 2028.

According to the Cleveland Clinic report, lymphedema can develop when there is damage to the lymphatic system or disruption in lymphatic damage. For example, lymph fluids drain into soft tissues, causing swelling and can occur anywhere in the body, with most cases occurring in arms and legs. Apart from that, cancer surgeries, radiation treatments, and other medical conditions raise the risk of lymphedema among patients. Additionally, among the gynecologic oncologic population, an increase in body mass index, insufficient levels of physical activity, and presence of pre-treatment lymphedema may be witnessed as potentially high-risk factors of lymphedema development. For example, oncological surgical procedures such as sentinel lymph nodes biopsy and radical dissection requiring excision of regional lymph nodes or vessels result in the development of secondary lymphedema. According to one report, lymphedema can occur after any cancer or its treatment affecting lymph node drainage. For example, it has been reported that it can occur within days and up to 30 years after the treatment for breast cancer. Also, 80% of patients experience onset within three years of surgery, and the remainder develops edema at a rate of 1% per year. Additionally, a large patient pool suffers from lower-limb lymphedema, particularly women after treatment for gynecological cancer, with the highest prevalence (36%) among vulvar cancer survivors and lowest prevalence (5%) among ovarian cancer survivors. Further, the overall incidence of arm lymphedema ranges from 8% to 56% at two years post-surgery. Furthermore, lymphedema may and do occur in the trunk, in addition to limbs. For example, radiation therapy to the chest wall is associated with the development of edema, particularly in the irradiated breast. Additionally, the healthcare system requires highly advanced treatment products. Therefore, major players are highly focusing on new and innovative product launches and approvals. Furthermore, with surging volume of lymphedema prevalence fuels the demand for lymphedema treatment ultimately contributing for the overall market growth.The world has watched several viruses such as SARS, H1N1, and others over the past few years. However, the severity of the coronavirus made the condition difficult. Coronavirus disease (COVID-19) is a contagious disease that has been affected by a newly discovered coronavirus. In the North American region, the United States was heavily impacted by the outbreak of the COVID-19 pandemic. The country has had the highest number of positive patients. COVID-19, first discovered in December in Wuhan, China, has made more than 203,456,777 people sick worldwide and killed at least 4.3 million people, according to Worldometer data as of August 9th, 2021. US coronavirus cases are increasing the most in the world. There have been around 36,543,338 confirmed cases of COVID-19 in the United States, with 633,116 deaths. The COVID-19 pandemic has brought about technological changes that are critical to better care. As the number of coronavirus cases climbs in the United States, many aspects of quarantine are becoming semi-permanent, at the very least. The prolonged shut-in situation is devastating news for countless industries impacted by business closures, but there are bright spots for sectors that have thrived amid the global health crisis so far. Lymphedema Treatment is one sector that has showed remarkable stamina. According to Marry Ann Libert, the COVID-19 lockdown had a great impact on lymphedema patients in both medical and psychological aspects across the United States.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the lymphedema treatment market. The North America lymphedema treatment market is expected to grow at a good CAGR during the forecast period.

North America Lymphedema Treatment Market Revenue and Forecast to 2028 (US$ Million)

North America Lymphedema Treatment Market Segmentation

North America Lymphedema Treatment Market – By Condition Type

• Primary Lymphedema
• Secondary Lymphedema

North America Lymphedema Treatment Market – By Treatment Type

• Laser Therapy
• Compression Devices
• Drug Therapy
• Physiological Procedures
  • Lymphovenous Anastomosis (LVA)
  • Vascularised Lymph Node Transfer (VLNT)
• Debulking Procedures
  • Surgical Debulking
  • Liposuction
  • Others
• Others

North America Lymphedema Treatment Market – By End-User

• Hospitals
• Clinics
• Clinical Research Organizations
• Others

North America Lymphedema Treatment Market- By Country

• US
• Canada
• Mexico

North America Lymphedema Treatment Market-Companies Mentioned

• 3M Company
• Bio Compression Systems Inc.
• BSN medical GmbH
• Huntleigh Healthcare Limited
• Lohmann & Rauscher GmbH & Co. KG
• Mego Afek ltd
• Sigvaris Group
• Smith & Nephew
• Tactile Medical
• ThermoTek

North America Lymphedema Treatment Report Scope